SynCardia Facebook SynCardia Twitter SynCardia LInkedIn SynCardia Google Plus SynCardia Youtube

SynCardia Systems, Inc.

Press Release:

SynCardia Honored with Membership in World Technology Network

Total Artificial Heart Manufacturer Joins Members from More Than 60 Countries Judged by Their Peers as the Most Innovative in the Technology World

SynCardia CEO/President Michael Garippa and his partner Kelly Kurpecky attend the 2011 World Technology Awards Gala on Oct. 26 at the United Nations. SynCardia was recognized as one of 6 finalists in the Health & Medicine category. SynCardia CEO/President Michael Garippa and his partner Kelly Kurpecky attend the 2011 World Technology Awards Gala on Oct. 26 at the United Nations. SynCardia was recognized as one of 6 finalists in the Health & Medicine category. TUCSON, Ariz. – Nov. 2, 2011 – SynCardia Systems, Inc., manufacturer of the SynCardia temporary Total Artificial Heart, announced today that it has been inducted into the World Technology Network (WTN) as a new Corporate Member. Membership can only occur through the annual Awards process, in which individuals and companies are selected via the judgment of the current WTN Fellows. SynCardia was selected as one of 6 finalists for the 2011 World Technology Award in Health & Medicine, presented in association with TIME, Fortune, CNN, Science/AAAS and Technology Review.

"SynCardia is very privileged to join this elite group of individuals and companies bringing important emerging technologies across the finish line throughout 20 different industries worldwide," said Michael Garippa, SynCardia CEO/President.

SynCardia was nominated for designing, developing and introducing the Freedom® portable driver, the first wearable power supply for the world's only FDA, Health Canada and CE approved Total Artificial Heart. For the first time in U.S. history, stable patients without human hearts are leaving the hospital to wait for a matching donor heart at home. The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S. 

Prior to the development of the 13.5 pound Freedom driver, U.S. Total Artificial Heart patients were confined to the hospital for months, sometimes years while they waited for a transplant because the only FDA-approved driver, "Big Blue," is hospital-based and weighs 418 pounds.  

WTN is a global meeting ground, a virtual think tank, and an elite club whose members are all focused on the business and science of bringing important emerging technologies of all types (from biotech to new materials, from IT to new energy sources) into reality. Membership is composed of more than 1000 scientists, entrepreneurs, financiers, journalists, academics, policymakers, etc., and more than 200 organizations/companies.

CAUTION – The Freedom® portable driver is an investigational device, limited by United States law to investigational use.

###

About SynCardia Systems, LLC
SynCardia Systems, LLC in Tucson, Ariz., is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. For people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure), the SynCardia temporary Total Artificial Heart is used as a bridge to transplant, helping them survive until a matching donor heart becomes available. SynCardia also manufactures the Freedom® portable driver, which powers the temporary Total Artificial Heart and allows clinically stable patients to be discharged from the hospital to enjoy life at home while they wait for a heart transplant.

Follow SynCardia: Facebook | Twitter | LinkedIn | Google+

SynCardia Contact:
Janelle Drumwright, jdrumwright@syncardia.com, (520) 547-7463

Search offcanvas